Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells

Biochemical and Biophysical Research Communications

Volumn 361, Issue 1, 2007, Pages 189-195

  Lambert, James R ^b   Young, Christian D ^b   Persons, Kelly S ^a   Ray, Rahul ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

1,25 Dihydroxyvitamin D3; 25 Hydroxyvitamin D3 derivative; Akt pathway; Apoptosis; Bio availability; Cellular uptake; Prostate cancer; Serum stability; Vitamin D receptor

Indexed keywords

BROMOACETIC ACID; CALCIFEDIOL; CALCITRIOL; PROTEIN KINASE B; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG UPTAKE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CALCIFEDIOL; CELL LINE, TUMOR; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CALCITRIOL;

EID: 34547115708     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.07.012     Document Type: Article

References (26)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer Statistics 2006. CA. Cancer J. Clin. 56 2 (2006) 106-130
2. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., Stampfer M.J., and Willett W.C. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J. Natl. Cancer Inst. 98 (2006) 451-459
3. Giovannucci E., Liu Y., Stampfer M.J., and Willett W.C. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 203-210
4. Wei E.K., Giovannucci E., Fuchs C.S., Willett W.C., and Mantzoros C.S. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J. Natl. Cancer Inst. 97 (2005) 1688-1694
5. Matsuda S., and Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol. Cancer Ther. 5 (2006) 797-808
6. Trump .D.L., Muindi J., Fakih M., Yu W.D., and Johnson C.J. Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res. 26 (2006) 2551-2556
7. Sutton A.L., and MacDonald P.N. Vitamin D: more than a "bone-a-fide'' hormone. Mol. Endocrinol. 17 (2003) 777-791
8. Fakih M.G., Trump D.L., Muindi J.R., Black J.D., Bernardi R.J., Creaven P.J., Schwartz J., Brattain M.G., Hutson A., French R., and Johnson C.S. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res. 13 (2007) 1216-1223
9. Trump D.L., Potter D.M., Muindi J., Brufsky A., and Johnson C.S. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 106 (2006) 2136-2142
10. Muindi J.R., Peng Y., Potter D.M., Hershberger P.A., Tauch J.S., Capozzoli M.J., Egorin M.J., Johnson C.S., and Trump D.L. Pharmacokinetics of high-dose oral calcitriol phase I trial of calcitriol and paclitaxel. Clin. Pharmacol. Ther. 72 (2003) 648-659
11. Hershberger P.A., Yu W.-D., Modzelewski R.A., Rueger R.M., Johnson C.S., and Trump D.L. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin. Cancer Res. 7 (2001) 1043-1051
12. Yu W.-D., McElwain M.C., Modzelewski R.A., Russell D.M., Smith D.C., Trump D.L., and Johnson C.S. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J. Natl. Cancer Inst. 90 (1998) 34-141
13. Smith D.C., Johnson C.S., Freeman C.C., Muindi J., Wilson J.W., and Trump D.L. A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin. Cancer Res. 5 (1999) 1339-1345
14. Dalhoff K., Dancey J., Astrup L., Skovsgaard T., Hamberg K.J., Lofts F.J., Rosmorduc O., Erlinger S., BachHansen J., Steward W.P., Skov T., Burcharth F., and Evans T.R. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer 89 (2003) 252-257
15. Evans T.R., Colston K.W., Lofts F.J., Cunningham D., Anthoney D.A., Gogas H., de Bono J.S., Hamberg K.J., Skov T., and Mansi J.L. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br. J. Cancer 86 (2002) 680-685
16. Schwartz G.G., Eads D., Rao A., Cramer S.D., Willingham M.C., Chen T.C., Jamieson D.P., Wang L., Burnstein K.L., Holick M.F., and Koumenis C. Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis 25 (2004) 1015-1026
17. Chen T.C., Schwartz G.G., Burnstein K.L., Lokeshwar B.L., and Holick M.F. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin. Cancer Res. 6 (2000) 901-908
18. 3 in prostate cancer cells. Clin. Cancer Res. 10 (2004) 8018-8027
19. Swamy N., and Ray R. Affinity labeling of rat serum vitamin D-binding protein. Arch. Biochem. Biophys. 333 (1996) 139-144
20. Hedlund T.E., Moffatt K.A., and Miller G.J. Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J. Steroid Biochem. Mol. Biol. 58 (1996) 277-288
21. Labarca C., and Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 102 (1980) 344-352
22. Swamy N., Addo J., and Ray R. Development of an affinity-driven double cross-linker: isolation of a ligand-activated factor, associated with vitamin D receptor-mediated transcriptional machinery. Bioorg. Med. Chem. Lett. 10 (2000) 361-364
23. 3 selectively induces bone formation. Proc. Natl. Acad. Sci. USA 99 (2002) 13487-13491
24. 3 (Ro-26-9228). Mol. Endocrinol. 18 (2004) 393-411
25. Gao N., Zhang Z., Jiang B.H., and Shi X. Role of PI3K/Akt/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Commun. 310 (2003) 1124-1132
26. Uzgare A.R., and Isaacs J.T. Enhanced redundancy of in Akt and mitogen-activated protein kinase induced survival of malignant versus normal prostate epithelia. Cencer Res. 64 (2004) 6190-6199